This approach, utilizing both blood and tumor tissue analysis, will enable a more nuanced comprehension of DYRK3’s role in oral squamous cell carcinoma and may contribute to the identification of novel diagnostic markers, prognostic indicators, or therapeutic targets for this particular type of cancer. Here, DYRK3 is linked to oral cavity squamous cell carcinoma.